Physician profile
Richard Jon Breen
NPI 1689667214
$42,838.99
in general payments reported to CMS, 2019-2025
32 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $582 · 2021: $1,235 · 2022: $1,438 · 2023: $6,975 · 2024: $1,387 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $26K · Food and Beverage: $4,844 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,275 · Travel and Lodging: $4,128 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $25,675.00 |
| Food and Beverage | $4,844.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,275.00 |
| Travel and Lodging | $4,127.52 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $36,873.96 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $966.15 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $931.74 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $549.61 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $409.02 | 2020-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $381.72 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $324.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.05 | 2019-2022 | |
| Sanofi Pasteur INC. | $229.01 | 2019-2024 | |
| Cranial Technologies, INC | $213.59 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $207.51 | 2019-2023 | Bexsero |
| Kowa Pharmaceuticals America, INC. | $180.89 | 2024-2025 | Zoryve |
| Seqirus USA INC | $180.84 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Rhodes Pharmaceuticals L.P. | $143.74 | 2019 | |
| Adlon Therapeutics L.P. | $133.78 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $115.69 | 2020-2023 | Auvi-Q |
| Vertical Pharmaceuticals, LLC | $101.52 | 2019-2025 | Relexxii |
| Astrazeneca Pharmaceuticals Lp | $74.67 | 2022-2023 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $64.65 | 2025 | Jornay Pm |
| Sobi, INC | $63.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $53.41 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $45.53 | 2022 | |
| Noven Therapeutics, LLC | $45.05 | 2023-2024 | Xelstrym |
| Shire North American Group INC | $44.07 | 2019 | |
| Biomarin Pharmaceutical INC. | $43.80 | 2024 | Voxzogo 1.2mg |
| Arbor Pharmaceuticals, INC. | $42.21 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $22.36 | 2019 | |
| Genentech USA, INC. | $21.17 | 2020 | |
| Biogen, INC. | $18.61 | 2021 | |
| Roche Diagnostics Corporation | $15.45 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.33 | 2019 | |
| Aytu Biopharma, INC. | $6.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.